Sensory-Evoked Cortical Gamma Oscillation

Description

The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeutic sensory stimulation device capable of evoking 40-Hz gamma oscillation via non-invasive visual and auditory stimulation with pre-established markers of cortical network activity, i.e., electroencephalography (EEG) and event-related potentials (ERP), to evaluate the applicability of the 40-Hz multimodel sensory stimulation as a novel therapeutic approach for treatment of AD patients.

Conditions

Alzheimer Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeutic sensory stimulation device capable of evoking 40-Hz gamma oscillation via non-invasive visual and auditory stimulation with pre-established markers of cortical network activity, i.e., electroencephalography (EEG) and event-related potentials (ERP), to evaluate the applicability of the 40-Hz multimodel sensory stimulation as a novel therapeutic approach for treatment of AD patients.

Sensory-Evoked Cortical Gamma Oscillation: Impact on Visual Processing and Cognitive Function in Patients With Alzheimer's Disease

Sensory-Evoked Cortical Gamma Oscillation

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

Knoxville

University of Tennessee Medical Center, Knoxville, Tennessee, United States, 37920

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011)
  • * Fluent and literate in English language
  • * Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research
  • * Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results
  • * Not fluent and literate in English
  • * Severe dementia
  • * Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities
  • * Cardiac pacemakers or any other implants that may not be compatible with MRI
  • * Cognitively impaired to the point the patient is unable to consent for themselves
  • * Claustrophobic to the point that medication is required

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Tennessee Medical Center,

Roberto Fernandez-Romero, MD, PRINCIPAL_INVESTIGATOR, University of Tennessee Medical Center

Study Record Dates

2026-06-30